The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

The trial is aimed at assessing long-term efficacy as well as safety of the therapy in 150 chronic HDV patients.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...